1281592
Last Update Posted: 2014-02-25
Recruiting has ended
All Genders accepted | 18 Years + |
36 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.
Eligibility
Relevant conditions:
Advanced or Metastatic Solid Tumours
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov